656238-22-1

Upstream product

• 105729-42-8 N,N'-bis(carbobenzyloxy)-L-cystine di-tert-butyl ester 
• 62574-13-4 L-cystine tert-butyl ester 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1337527-03-3 (R)-tert-butyl 2-(benzyloxycarbonylamino)-3-( (S)-2,3-bis( methylsulfonyloxy)propylthio)-propanoate 
• 1337527-04-4 (R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((R)-2,3-diazidopropylthio)propanoate 
• 1337527-05-5 (R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((R)-2,3-diaminopropylthio)propanoate 
• 1337527-06-6 (5R,9R)-tert-butyl 9-dodecanamido-3,12-dioxo-1-phenyl-2-oxa-7-thia-4,11-diazatricosane-5-carboxylate 
• 1337527-07-7 (5R,9R)-9-dodecanamido-3,12-dioxo-1-phenyl-2-oxa-7-thia-4,11-diazatricosane-5-carboxylic acid 
• 1337527-08-8 benzyl (R)-3-((R)-2,3-didodecanamidopropylthio)-1-(1-(hydroxymethyl)cyclopropylamino)-1-oxopropan-2-ylcarbamate 
• 1337527-58-8 (R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((R)-2,3-bis(decylcarbamoyloxy)propylthio)propanoate 
• 1337527-56-6 C₃₆H₆₁N₃O₈S 
• 1337527-59-9 (14R,18R)-14-(benzyloxycarbonylamino)-18-(decylcarbamoyloxy)-13,21-dioxo-3,6,9,20-tetraoxa-16-thia-12,22-diazadotriacontylphosphonic acid diethyl ester 
• 1337527-60-2 (15R,19R)-tert-butyl 15-(benzyloxycarbonylamino)-19-(decylcarbamoyloxy)-14,22-dioxo-4,7,10,21-tetraoxa-17-thia-13, 23-diazatritriacontan-1-oate 
• 1337527-62-4 (R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((R)-2,3-bis(octylcarbamoyloxy)propylthio)propanoate 
• 1337527-63-5 (R)-2-(benzyloxycarbonylamino )-3-((R)-2,3-bis(octylcarbamoyloxy)propylthio)propanoic acid 
• 1337527-69-1 (14R,18R)-14-(benzyloxycarbonylamino)-18-(octylcarbamoyloxy )-13,21-dioxo-3,6,9,20-tetraoxa-16-thia-12,22-diazatriacontylphosphonic acid diethyl ester 
• 1337527-02-2 (R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((S)-2,3-dihydroxypropylthio)propanoate 

Relevant academic research and scientific papers

COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC.

The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.